You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Several analysts said that the decision by UHC, the largest private payor in the US, will especially benefit Natera.
The firm said it will dispute the claim of overpayment and will separately negotiate with the undisclosed payor for in-network status.
As a result of the expanded coverage, Natera said it believes there are currently 139 million people covered in the US for average risk NIPT.
The agency issued a new draft decision memo, outlining various criteria it intends to apply when determining coverage for current and future blood-based CRC screening tests.
Myriad Genetics' EndoPredict, Agendia's MammaPrint (distributed in Germany by PathoNext), and Veracyte's Prosigna will now be covered by public insurance.
Natera said that the expanded coverage by Centene will add 24 million people for whom the Panorama noninvasive prenatal test will be covered.
After a two-year evaluation in advanced non-small cell lung cancers with Allegheny Health Network, the payor will cover the test for its regional members.
Saying pooled testing for coronavirus was not for diagnostic purposes, Cigna had said it wouldn't reimburse for the method, but it plans to change its policy.
NantHealth's net loss more than tripled in the second quarter, though it continues to build up its cash reserves.
Researchers concluded that there has been significant expansion of coverage for ctDNA assays over the past four years, but policies remain very heterogeneous and often limited.